Future regenerative therapies will demand higher performance and shorter recovery times with targeted delivery options.


Theradaptive is shaping the future of regenerative medicine with a new platform to deliver therapeutics that promote targeted native tissue repair.


Contact us to learn how


Theradaptive selected as the sole recipient of the 2018 Maryland Stem Cell Research Fund Commercialization Grant.

Theradaptive Selected as a Finalist at the 2018 First Coast Innovation Challenge in Boston

Theradaptive selected for Phase II funding under the Defense Health Program Small Business Innovation Research Program to develop osteochondral repair implants with biologic delivery capability. 

Theradaptive partners on a $1.47M DoD Contract to develop next-gen 3D printed drug eluting spinal fusion devices

© 2017-2019 by Theradaptive, Inc.